Article Cited by others

INVITED REVIEW

Poly (ADP-ribose) polymerase inhibitor: an evolving paradigm in the treatment of prostate cancer

Zhang Jingsong

Year : 2014| Volume: 16| Issue : 3 | Page no: 401-406

   This article has been cited by
 
1 Pharmacological inhibition of poly (ADP-ribose) polymerase by olaparib, prevents acute lung injury associated cognitive deficits potentially through suppression of inflammatory response
Bijayani Sahu,Arun Narota,Amarjit S. Naura
European Journal of Pharmacology. 2020; : 173091
[Pubmed]  [Google Scholar] [DOI]
2 Circulating tumor cells and ?H2AX as biomarkers for responsiveness to radium-223 in advanced prostate cancer patients
Jonathan Chatzkel,Jesse Mocha,Johnna Smith,Jun-Min Zhou,Youngchul Kim,Ghassan El-Haddad,Jingsong Zhang
Future Science OA. 2019; : FSO437
[Pubmed]  [Google Scholar] [DOI]
3 Proteomic Characterization of Prostate Cancer to Distinguish Nonmetastasizing and Metastasizing Primary Tumors and Lymph Node Metastases
Ann-Kathrin Müller,Melanie Föll,Bianca Heckelmann,Selina Kiefer,Martin Werner,Oliver Schilling,Martin L. Biniossek,Cordula Annette Jilg,Vanessa Drendel
Neoplasia. 2018; 20(2): 140
[Pubmed]  [Google Scholar] [DOI]
4 PARP inhibitors as potential therapeutic agents for various cancers: focus on niraparib and its first global approval for maintenance therapy of gynecologic cancers
Mekonnen Sisay,Dumessa Edessa
Gynecologic Oncology Research and Practice. 2017; 4(1)
[Pubmed]  [Google Scholar] [DOI]
5 “Back to a false normality”: new intriguing mechanisms of resistance to PARP inhibitors
Lorena Incorvaia,Francesc Passiglia,Sergio Rizzo,Antonio Galvano,Angela List?,Nadia Barraco,Rossella Maragliano,Valentina Calň,Clara Natoli,Marcello Ciaccio,Viviana Bazan,Antonio Russo
Oncotarget. 2017; 8(14): 23891
[Pubmed]  [Google Scholar] [DOI]
6 PARP Inhibitors in Prostate Cancer
Praveen Ramakrishnan Geethakumari,Matthew J. Schiewer,Karen E. Knudsen,Wm. Kevin Kelly
Current Treatment Options in Oncology. 2017; 18(6)
[Pubmed]  [Google Scholar] [DOI]
7 Association between single-nucleotide polymorphisms in DNA double-strand break repair genes and prostate cancer aggressiveness in the Spanish population
L A Henríquez-Hernández,A Valenciano,P Foro-Arnalot,M J Álvarez-Cubero,J M Cozar,J F Suárez-Novo,M Castells-Esteve,P Fernández-Gonzalo,B De-Paula-Carranza,M Ferrer,F Guedea,G Sancho-Pardo,J Craven-Bartle,M J Ortiz-Gordillo,P Cabrera-Roldán,J I Rodríguez-Melcón,E Herrera-Ramos,C Rodríguez-Gallego,P C Lara
Prostate Cancer and Prostatic Disease. 2016; 19(1): 28
[Pubmed]  [Google Scholar] [DOI]
8 PARP inhibitor, olaparib ameliorates acute lung and kidney injury upon intratracheal administration of LPS in mice
Kunal Kapoor,Esha Singla,Bijayani Sahu,Amarjit S. Naura
Molecular and Cellular Biochemistry. 2015; 400(1-2): 153
[Pubmed]  [Google Scholar] [DOI]
9 Pre-radiotherapy identification of individual genomic profile to avoid, by resort to customized radiosensitizers, the risk of radioresistance development in patients with localized prostate cancer
C Alberti
The British Journal of Radiology. 2015; 88(1045): 20140630
[Pubmed]  [Google Scholar] [DOI]
10 Expression of nuclear matrix proteins binding matrix attachment regions in prostate cancer. PARP-1: New player in tumor progression
Paola Barboro,Nicoletta Ferrari,Matteo Capaia,Andrea Petretto,Sandra Salvi,Simona Boccardo,Cecilia Balbi
International Journal of Cancer. 2015; 137(7): 1574
[Pubmed]  [Google Scholar] [DOI]

 

Read this article